Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants

Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

Liu, Z., VanBlargan, L. A., Bloyet, L.-M., Rothlauf, P. W., Chen, R. E., Stumpf, S., Zhao, H., Errico, J. M., Theel, E. S., Liebeskind, M. J., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.01.014 · Cited by 725

Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite

Cerutti, G., Guo, Y., Zhou, T., Gorman, J., Lee, M., Rapp, M., Reddem, E. R., Yu, J., Bahna, F., Bimela, J., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.03.005 · Cited by 519

The variant gambit: COVID-19’s next move

Plante, J. A., Mitchell, B. M., Plante, K. S., Debbink, K., Weaver, S. C., & Menachery, V. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.020 · Cited by 328

Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant

Edara, V. V., Norwood, C., Floyd, K., Lai, L., Davis-Gardner, M. E., Hudson, W. H., Mantus, G., Nyhoff, L. E., Adelman, M. W., Fineman, R., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.03.009 · Cited by 224

Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS‐CoV‐2 Neutralizing Antibodies

Vanderheiden, A., Edara, V. V., Floyd, K. A., Kauffman, R. C., Mantus, G. E., Anderson, E. J., Rouphael, N., Edupuganti, S., Shi, P., Menachery, V. D., et al. (2020) · Current Protocols in Immunology · doi:10.1002/cpim.116 · Cited by 134

Mechanisms of SARS-CoV-2 entry into cells

Jackson, C. B., Farzan, M., Chen, B., & Choe, H. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00418-x · Cited by 3,022

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Planas, D., Veyer, D., Baidaliuk, A., Staropoli, I., Guivel-Benhassine, F., Rajah, M. M., Planchais, C., Porrot, F., Robillard, N., Puech, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03777-9 · Cited by 1,992

The biological and clinical significance of emerging SARS-CoV-2 variants

Tao, K., Tzou, P. L., Nouhin, J., Gupta, R. K., de Oliveira, T., Kosakovsky Pond, S. L., Fera, D., & Shafer, R. W. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00408-x · Cited by 1,009

Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review

Fiolet, T., Kherabi, Y., MacDonald, C.-J., Ghosn, J., & Peiffer-Smadja, N. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.10.005 · Cited by 911

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis

Cromer, D., Steain, M., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Kent, S. J., Triccas, J. A., Khoury, D. S., & Davenport, M. P. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00267-6 · Cited by 590

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination

Pajon, R., Doria-Rose, N. A., Shen, X., Schmidt, S. D., O'Dell, S. J., McDanal, C., Feng, W., Tong, J., Eaton, A., Maglinao, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119912 · Cited by 447

Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant

Zhang, J., Xiao, T., Cai, Y., Lavine, C. L., Peng, H., Zhu, H., Anand, K., Tong, P., Gautam, A. K., Mayer, M. L., et al. (2021) · Science · doi:10.1126/science.abl9463 · Cited by 288

Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants

McCallum, M., Walls, A. C., Sprouse, K. R., Bowen, J. E., Rosen, L. E., Dang, H. V., Marco, A. D., Franko, N., Tilles, S. W., Logue, J. K., et al. (2021) · Science · doi:10.1126/science.abl8506 · Cited by 280

Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination

Cho, A., Muecksch, F., Schaefer-Babajew, D. J., Wang, Z., Finkin, S., Gaebler, C., Ramos, V., Cipolla, M., Mendoza, P., Agudelo, M., et al. (2021) · Nature · doi:10.1038/s41586-021-04060-7 · Cited by 263

Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individualsPreprint

Planas, D., Veyer, D. L., Baidaliuk, A., Staropoli, I., Guivel‐Benhassine, F., Rajah, M. M., Planchais, C., Porrot, F., Robillard, N., Puech, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.26.445838 · Cited by 272

The germinal centre B cell response to SARS-CoV-2

Laidlaw, B. J., & Ellebedy, A. H. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00657-1 · Cited by 268

Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety

Mascellino, M. T., Timoteo, F. D., Angelis, M. D., & Oliva, A. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s315727 · Cited by 265

SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants

Martínez-Flores, D., Zepeda–Cervantes, J., Cruz-Reséndiz, A., Aguirre‐Sampieri, S., Sampieri, A., & Vaca, L. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.701501 · Cited by 244

Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors

Shroff, R. T., Chalasani, P., Wei, R., Pennington, D., Quirk, G., Schoenle, M. V., Peyton, K. L., Uhrlaub, J. L., Ripperger, T. J., Jergović, M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01542-z · Cited by 237

SARS-COV-2 Variants: Differences and Potential of Immune Evasion

Hirabara, S. M., Serdan, T. D. A., Gorjão, R., Masi, L. N., Pithon‐Curi, T. C., Covas, D. T., Curi, R., & Durigon, E. L. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.781429 · Cited by 220

A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson

Patel, R. S., Kaki, M., Potluri, V., Kahar, P., & Khanna, D. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.2002083 · Cited by 252

mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant

Edara, V. V., Manning, K. E., Ellis, M. L., Lai, L., Moore, K. M., Foster, S. L., Floyd, K. A., Davis-Gardner, M. E., Mantus, G. E., Nyhoff, L. E., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100529 · Cited by 209

mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron

Gagné, M., Moliva, J. I., Foulds, K. E., Andrew, S. F., Flynn, B. J., Werner, A. P., Wagner, D. A., Teng, I., Lin, B. C., Moore, C. A., et al. (2022) · Cell · doi:10.1016/j.cell.2022.03.038 · Cited by 209

The Global Epidemic of the SARS-CoV-2 Delta Variant, Key Spike Mutations and Immune Escape

Tian, D., Sun, Y., Zhou, J., & Ye, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.751778 · Cited by 201

Immune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far?

Lazarević, I., Pravica, V., Miljanovic, D., & Cupic, M. D. (2021) · Viruses · doi:10.3390/v13071192 · Cited by 193

Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals

(2022) · doi:10.1016/j.cell.2022.01.027 · Cited by 179

Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and virus transmission

Escalera, A., Gonzalez-Reiche, A. S., Aslam, S., Mena, I., Laporte, M., Pearl, R. L., Fossati, A., Rathnasinghe, R., Alshammary, H., van de Guchte, A., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.01.006 · Cited by 173

Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study

Sonabend, R., Whittles, L. K., Imai, N., Perez-Guzman, P. N., Knock, E. S., Rawson, T., Gaythorpe, K. A. M., Djaafara, B. A., Hinsley, W. R., FitzJohn, R. G., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02276-5 · Cited by 160

Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant

Lyke, K. E., Atmar, R. L., Islas, C. D., Posavad, C. M., Szydlo, D., Paul Chourdhury, R., Deming, M. E., Eaton, A., Jackson, L. A., Branche, A. R., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100679 · Cited by 153

mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial

Oosting, S. F., van der Veldt, A. A. M., GeurtsvanKessel, C. H., Fehrmann, R. S. N., van Binnendijk, R. S., Dingemans, A. C., Smit, E. F., Hiltermann, T. J. N., den Hartog, G., Jalving, M., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00574-x · Cited by 150

COVID‐19 vaccinations: The unknowns, challenges, and hopes

Mohamed, K., Rzymski, P., Islam, M. S., Makuku, R., Mushtaq, A., Khan, A., Ivanovska, M., Makka, S. A., Hashem, F., Marquez, L. P., et al. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27487 · Cited by 151

SARS‐CoV‐2 variants and vulnerability at the global level

Chavda, V. P., Patel, A., & Vaghasiya, D. D. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27717 · Cited by 135

SARS-CoV-2: Evolution and Emergence of New Viral Variants

Flores-Vega, V. R., Monroy-Molina, J. V., Jiménez-Hernández, L. E., Torres, A. G., Santos, J. I., & Rosales-Reyes, R. (2022) · Viruses · doi:10.3390/v14040653 · Cited by 127

Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner

Keeton, R., Richardson, S. I., Moyo-Gwete, T., Hermanus, T., Tincho, M. B., Benede, N., Manamela, N. P., Baguma, R., Makhado, Z., Ngomti, A., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.10.003 · Cited by 109

Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies

Zhou, H., Tada, T., Dcosta, B. M., & Landau, N. R. (2022) · Viruses · doi:10.3390/v14061334 · Cited by 108

Reinfection in patients with COVID-19: a systematic review

Ren, X., Zhou, J., Guo, J., Hao, C., Zheng, M., Zhang, R., Huang, Q. Y., Yao, X., Li, R., & Jin, Y. (2022) · Global Health Research and Policy · doi:10.1186/s41256-022-00245-3 · Cited by 104

An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines

Hillary, V. E., & Ceasar, S. A. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13952 · Cited by 121

Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern

Dupont, L., Snell, L. B., Graham, C., Seow, J., Merrick, B., Lechmere, T., Maguire, T. J. A., Hallett, S. R., Pickering, S., Charalampous, T., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-021-00974-0 · Cited by 102

COVID-19: Challenges of Viral Variants

Jacobs, J. L., Haidar, G., & Mellors, J. W. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-042921-020956 · Cited by 105

Delta variant (B.1.617.2) of SARS-CoV-2: Mutations, impact, challenges and possible solutions

Dhawan, M. K., Sharma, A., Choudhary, P., Thakur, N., Rajkhowa, T. K., & Choudhary, O. P. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2068883 · Cited by 116

The global epidemic of SARS‐CoV‐2 variants and their mutational immune escape

Tian, D., Sun, Y., Zhou, J., & Ye, Q. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27376 · Cited by 106

The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far

Chavda, V. P., Bezbaruah, R., Deka, K., Nongrang, L., & Kalita, T. (2022) · Vaccines · doi:10.3390/vaccines10111926 · Cited by 108

Accelerated waning of the humoral response to COVID-19 vaccines in obesity

van der Klaauw, A. A., Horner, E. C., Pereyra-Gerber, P., Agrawal, U., Foster, W. S., Spencer, S., Vergese, B., Smith, M., Henning, E., Ramsay, I. D., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02343-2 · Cited by 106

Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience

Peled, Y., Ram, E., Ii Jacob Lavee, I., Segev, A., Matezky, S., Wieder-Finesod, A., Halperin, R., Mandelboim, M., Indenbaum, V., Levy, I., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.08.010 · Cited by 99

Durability of immune responses to mRNA booster vaccination against COVID-19

Arunachalam, P. S., Lai, L., Samaha, H., Feng, Y., Hu, M., Hui, H. S.-Y., Wali, B., Ellis, M. L., Davis-Gardner, M. E., Huerta, C., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci167955 · Cited by 105

Structure, receptor recognition, and antigenicity of the human coronavirus CCoV-HuPn-2018 spike glycoprotein

Tortorici, M. A., Walls, A. C., Joshi, A., Park, Y., Eguia, R. T., Miranda, M. C., Kepl, E., Dosey, A. M., Stevens‐Ayers, T., Boeckh, M. J., et al. (2022) · Cell · doi:10.1016/j.cell.2022.05.019 · Cited by 89

Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021

Bozio, C. H., Grannis, S. J., Naleway, A. L., Ong, T. C., Butterfield, K. A., DeSilva, M. B., Natarajan, K., Yang, D., Rao, S., Klein, N. P., et al. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7044e1 · Cited by 90

Persistence of neutralizing antibodies a year after SARS‐CoV‐2 infection in humans

Haveri, A., Ekström, N., Solastie, A., Virta, C., Österlund, P., Isosaari, E., Nohynek, H., PALMU, A. A. I., & Melin, M. M. (2021) · European Journal of Immunology · doi:10.1002/eji.202149535 · Cited by 92

Conformational dynamics of the Beta and Kappa SARS-CoV-2 spike proteins and their complexes with ACE2 receptor revealed by cryo-EM

Wang, Y., Xu, C., Wang, Y., Qin, H., Zhang, C., Li, Z., Xu, S., Zuo, Q., Liu, C., Huang, Z. W., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27350-0 · Cited by 85

Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers

Moncunill, G., Aguilar, R., Ribes, M., Ortega, N., Rubio, R., Salmerón, G., Molina, M. J., Vidal, M., Barrios, D., Mitchell, R. A., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2021.103805 · Cited by 74

A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants

Schmitz, A. J., Turner, J. S., Liu, Z., Zhou, J. Q., Aziati, I. D., Chen, R. E., Joshi, A., Bricker, T. L., Darling, T. L., Adelsberg, D. C., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.08.013 · Cited by 62

Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung

Gagné, M., Corbett, K. S., Flynn, B. J., Foulds, K. E., Wagner, D. A., Andrew, S. F., Todd, J.-P. M., Honeycutt, C. C., McCormick, L., Nurmukhambetova, S. T., et al. (2021) · Cell · doi:10.1016/j.cell.2021.12.002 · Cited by 71

A public vaccine-induced human antibody protects against SARS-CoV-2 and emerging variants

Schmitz, A. J., Turner, J. S., Liu, Z., Aziati, I. D., Chen, R. E., Joshi, A., Bricker, T. L., Darling, T. L., Adelsberg, D. C., Alsoussi, W. B., et al. (2021) · doi:10.1101/2021.03.24.436864 · Cited by 72

COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network

Ludwig, H., Sonneveld, P., Facon, T. T. F., Miguel, J. F. S., Avet‐Loiseau, H., Mohty, M., Mateos, M.-V., Moreau, P., Cavo, M., Pawlyn, C., et al. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00278-7 · Cited by 66

SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence

Tatsi, E., Filippatos, F., & Michos, A. G. (2021) · Epidemiology and Infection · doi:10.1017/s0950268821002430 · Cited by 68

B.1.617.2 (Delta) Variant of SARS-CoV-2: features, transmission and potential strategies

Zhan, Y., Yin, H. Y., & Yin, J. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.66881 · Cited by 68

Accelerating PERx reaction enables covalent nanobodies for potent neutralization of SARS-CoV-2 and variants

(2022) · doi:10.1016/j.chempr.2022.07.012 · Cited by 64

Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates

Gagné, M., Flynn, B. J., Andrew, S. F., Marquez, J., Flebbe, D. R., Mychalowych, A., Lamb, E., Davis-Gardner, M. E., Burnett, M. R., Serebryannyy, L., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01951-5 · Cited by 78

Antigenic characterization of influenza and SARS-CoV-2 viruses

Wang, Y., Tang, C. Y., & Wan, X. (2021) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-021-03806-6 · Cited by 62

The ins and outs of SARS-CoV-2 variants of concern (VOCs)

Salehi-Vaziri, ‪., Fazlalipour, M., Khorrami, S. M. S., Azadmanesh, K., Pouriayevali, M. H., Jalali, T., Shoja, Z., & Maleki, A. (2022) · Archives of Virology · doi:10.1007/s00705-022-05365-2 · Cited by 61

Durability of immune responses to the BNT162b2 mRNA vaccine

Suthar, M. S., Arunachalam, P. S., Hu, M., Reis, N., Trisal, M., Raeber, O., Chinthrajah, R. S., Davis-Gardner, M. E., Manning, K. E., Mudvari, P., et al. (2022) · Med · doi:10.1016/j.medj.2021.12.005 · Cited by 63

SARS-CoV-2 Neutralization Resistance Mutations in Patient with HIV/AIDS, California, USA

Hoffman, S. A., Costales, C., Sahoo, M. K., Palanisamy, S., Yamamoto, F. F., Huang, C., Verghese, M., Solis, D., Sibai, M., Subramanian, A. K., et al. (2021) · Emerging infectious diseases · doi:10.3201/eid2710.211461 · Cited by 55

SARS-CoV-2 Delta Variant Pathogenesis and Host Response in Syrian Hamsters

Mohandas, S., Yadav, P. D., Shete, A. M., Nyayanit, D. A., Sapkal, G. N., Lole, K. S., & Gupta, N. (2021) · Viruses · doi:10.3390/v13091773 · Cited by 56

Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial

Chiuppesi, F., Zaia, J. A., Frankel, P. H., Stan, R., Drake, J., Williams, B., Acosta, A. M., Francis, K., Taplitz, R. A., Dickter, J. K., et al. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00027-1 · Cited by 55

The way of SARS-CoV-2 vaccine development: success and challenges

Dong, Y., Dai, T., Wang, B., Zhang, L., Zeng, L., Huang, J., Yan, H., Zhang, L., & Zhou, F. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00796-w · Cited by 53

Durable protection against the SARS-CoV-2 Omicron variant is induced by an adjuvanted subunit vaccine

Arunachalam, P. S., Feng, Y., Ashraf, U., Hu, M., Walls, A. C., Edara, V. V., Zarnitsyna, V. I., Aye, P. P., Golden, N., Miranda, M. C., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq4130 · Cited by 53

Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant

Valanparambil, R. M., Carlisle, J. W., Linderman, S. L., Akhtar, A., Millett, R. L., Lai, L., Chang, A., McCook‐Veal, A. A., Switchenko, J. M., Nasti, T. H., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02986 · Cited by 48

The challenges of COVID‐19 Delta variant: Prevention and vaccine development

He, X., He, C., Hong, W., Zhang, K., & Wei, X. (2021) · MedComm · doi:10.1002/mco2.95 · Cited by 52

COVID‐19: A systematic review and update on prevention, diagnosis, and treatment

Aliabadi, H. A. M., Eivazzadeh‐Keihan, R., Parikhani, A. B., Mehraban, S. F., Maleki, A. R., Fereshteh, S., Bazaz, M., Zolriasatein, A., Bozorgnia, B., Rahmati, S., et al. (2022) · MedComm · doi:10.1002/mco2.115 · Cited by 50

Risk of SARS-CoV-2 reinfections in children: a prospective national surveillance study between January, 2020, and July, 2021, in England

Mensah, A. A., Campbell, H., Stowe, J., Seghezzo, G., Simmons, R., Lacy, J., Bukasa, A., O’Boyle, S., Ramsay, M. E., Brown, K. E., et al. (2022) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(22)00059-1 · Cited by 48

Age-associated B cells predict impaired humoral immunity after COVID-19 vaccination in patients receiving immune checkpoint blockade

Yam‐Puc, J. C., Hosseini, Z., Horner, E. C., Gerber, P. P., Beristain‐Covarrubias, N., Hughes, R., Lulla, A., Rust, M., Boston, R. H., Ali, M. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38810-0 · Cited by 53

Human Organoids and Organs‐on‐Chips for Addressing COVID‐19 Challenges

Wang, Y., Wang, P., & Qin, J. (2022) · Advanced Science · doi:10.1002/advs.202105187 · Cited by 48

Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma

Nooka, A. K., Shanmugasundaram, U., Cheedarla, N., Verkerke, H., Edara, V. V., Valanparambil, R. M., Kaufman, J. L., Hofmeister, C. C., Joseph, N. S., Lonial, S., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02257 · Cited by 46

Emergence of SARS-CoV-2 Variants in the World: How Could This Happen?

Parra-Lucares, A., Segura, P., Rojas, V. A., Pumarino, C., Saint-Pierre, G., & Toro, L. (2022) · Life · doi:10.3390/life12020194 · Cited by 49

Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses

Balachandran, H., Phetsouphanh, C., Agapiou, D., Adhikari, A., Rodrigo, C., Hammoud, M., Shrestha, L. B., Keoshkerian, E., Gupta, M., Turville, S. G., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110345 · Cited by 45

Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Chang, A., Akhtar, A., Linderman, S. L., Lai, L., Orellana-Noia, V. M., Valanparambil, R., Ahmed, H., Zarnitsyna, V. I., McCook-Veal, A. A., Switchenko, J. M., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00088 · Cited by 44

SARS-CoV-2 journey: from alpha variant to omicron and its sub-variants

Hattab, D., Amer, M. F. A., Al‐Alami, Z. M., & Bakhtiar, A. (2024) · Infection · doi:10.1007/s15010-024-02223-y · Cited by 48

Fighting the SARS-CoV-2 pandemic requires a global approach to understanding the heterogeneity of vaccine responses

Tomalka, J. A., Suthar, M. S., Deeks, S. G., & Sékaly, R. (2022) · Nature Immunology · doi:10.1038/s41590-022-01130-4 · Cited by 45

Individual genetic variability mainly of Proinflammatory cytokines, cytokine receptors, and toll‐like receptors dictates pathophysiology of COVID‐19 disease

Vakil, M. K., Mansoori, Y., Al‐Awsi, G. R. L., Hosseinipour, A., Ahsant, S., Ahmadi, S., Ekrahi, M., Montaseri, Z., Pezeshki, B., Mohaghegh, P., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27849 · Cited by 42

Epidemiological drivers of transmissibility and severity of SARS-CoV-2 in England

Perez-Guzman, P. N., Knock, E., Imai, N., Rawson, T., Santoni, C. N., Alcada, J., Whittles, L. K., Thekke Kanapram, D., Sonabend, R., Gaythorpe, K. A. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39661-5 · Cited by 42

Characterization of SARS-CoV-2 Spike mutations important for infection of mice and escape from human immune sera

Rathnasinghe, R., Jangra, S., Ye, C., Čupić, A., Singh, G., Martínez‐Romero, C., Mulder, L. C. F., Kehrer, T., Yildiz, S., Choi, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30763-0 · Cited by 42

The past, current and future epidemiological dynamic of SARS-CoV-2

Balloux, F., Tan, C. C. S., Swadling, L., Richard, D., Jenner, C., Maini, M. K., & van Dorp, L. (2022) · Oxford Open Immunology · doi:10.1093/oxfimm/iqac003 · Cited by 41

COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn

Muñoz, F. M., Posavad, C. M., Richardson, B. A., Badell, M. L., Bunge, K. E., Mulligan, M. J., Parameswaran, L., Kelly, C. W., Olson‐Chen, C., Novak, R. M., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.06.032 · Cited by 50

Design of a mutation-integrated trimeric RBD with broad protection against SARS-CoV-2

Liang, Y., Zhang, J., Yuan, R. Y., Wang, M. Y., He, P., Su, J. G., Han, Z. B., Jin, Y. Q., Hou, J. W., Zhang, H., et al. (2022) · Cell Discovery · doi:10.1038/s41421-022-00383-5 · Cited by 42

The rapid adaptation of SARS-CoV-2–rise of the variants: transmission and resistance

Soh, S. M., Kim, Y., Kim, C., Jang, U. S., & Lee, H.-R. (2021) · The Journal of Microbiology · doi:10.1007/s12275-021-1348-5 · Cited by 39

Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike

Changrob, S., Fu, Y., Guthmiller, J. J., Halfmann, P., Li, L., Stamper, C. T., Dugan, H. L., Accola, M., Rehrauer, W., Zheng, N.-Y., et al. (2021) · mBio · doi:10.1128/mbio.02975-21 · Cited by 40

Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination

Mantus, G. E., Nyhoff, L. E., Edara, V. V., Zarnitsyna, V. I., Ciric, C. R., Flowers, M. W., Norwood, C., Ellis, M. L., Hussaini, L., Manning, K. E., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100603 · Cited by 37

Anti- SARS-CoV-2 Receptor Binding Domain Antibody Evolution after mRNA Vaccination

Cho, A., Muecksch, F., Schaefer-Babajew, D., Wang, Z., Finkin, S., Gaebler, C., Ramos, V., Cipolla, M., Mendoza, P., Agudelo, M., et al. (2021) · doi:10.1101/2021.07.29.454333 · Cited by 275

SARS-CoV-2 breakthrough infections enhance T cell response magnitude, breadth, and epitope repertoire

Tarke, A., Ramezani-Rad, P., Neto, T. A. P., Lee, Y., Silva‐Moraes, V., Goodwin, B., Bloom, N. I., Siddiqui, L., Avalos, L., Frazier, A., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101583 · Cited by 38

Nanotechnology for the management of COVID-19 during the pandemic and in the post-pandemic era

Xu, C., Lei, C., Hosseinpour, S., Ivanovski, S., Walsh, L. J., & Khademhosseini, A. (2022) · National Science Review · doi:10.1093/nsr/nwac124 · Cited by 39

SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies

Focosi, D., Tuccori, M., Baj, A., & Maggi, F. (2021) · Viruses · doi:10.3390/v13071211 · Cited by 37

Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia

Parry, H., McIlroy, G., Bruton, R. K., Damery, S. L., Tyson, G. B., Logan, N. A., Davis, C., Willett, B. J., Zuo, J., Ali, M., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01219-7 · Cited by 33

Serological Cross-Reactivity in Zoonotic Flaviviral Infections of Medical Importance

da Silva, P. G., dos Reis, J. A. S., Rodrigues, M. N., Ardaya, Q. D. S., & Mesquita, J. R. (2023) · Antibodies · doi:10.3390/antib12010018 · Cited by 35

SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity

Neerukonda, S. N., Vassell, R. A., Lusvarghi, S., Wang, R., Echegaray, F., Bentley, L., Eakin, A. E., Erlandson, K. J., Katzelnick, L. C., Weiss, C. D., et al. (2021) · Viruses · doi:10.3390/v13122485 · Cited by 31

SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern

Hawman, D. W., Meade-White, K. D., Archer, J. F., Leventhal, S. S., Wilson, D., Shaia, C., Randall, S., Khandhar, A. P., Krieger, K., Hsiang, T.-Y., et al. (2022) · eLife · doi:10.7554/elife.75537 · Cited by 34

COVID-19: Epidemiologie und Mutationen

Hemmer, C. J., Löbermann, M., & Reisinger, E. C. (2021) · Der Radiologe · doi:10.1007/s00117-021-00909-0 · Cited by 33

The Immune Response to SARS-CoV-2 and Variants of Concern

Torbati, E., Krause, K. L., & Ussher, J. E. (2021) · Viruses · doi:10.3390/v13101911 · Cited by 36

The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines

Jiang, Y., Wu, Q. Y., Song, P., & You, C. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.806641 · Cited by 34

Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections

Azeem, M. I., Nooka, A. K., Shanmugasundaram, U., Cheedarla, N., Potdar, S. V., Manalo, R. J., Moreno, A., Switchenko, J. M., Cheedarla, S., Doxie, D. B., et al. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-22-0173 · Cited by 31

Short-term immune response after inactivated SARS-CoV-2 (CoronaVac®, Sinovac) and ChAdOx1 nCoV-19 (Vaxzevria®, Oxford-AstraZeneca) vaccinations in health care workers

Jantarabenjakul, W., Chantasrisawad, N., Puthanakit, T., Wacharapluesadee, S., Hirankarn, N., Ruenjaiman, V., Paitoonpong, L., Suwanpimolkul, G., Torvorapanit, P., Pradit, R., et al. (2021) · Asian Pacific Journal of Allergy and Immunology · doi:10.12932/ap-250721-1197 · Cited by 31

The intestinal microbiota and improving the efficacy of COVID-19 vaccinations

Chen, J., Vitetta, L., Henson, J. D., & Hall, S. (2021) · Journal of Functional Foods · doi:10.1016/j.jff.2021.104850 · Cited by 32

Facing the wrath of enigmatic mutations: a review on the emergence of severe acute respiratory syndrome coronavirus 2 variants amid coronavirus disease‐19 pandemic

Chadha, J., Khullar, L., & Mittal, N. (2021) · Environmental Microbiology · doi:10.1111/1462-2920.15687 · Cited by 33

Humoral and cellular responses to spike of δ SARS-CoV-2 variant in vaccinated patients with immune-mediated inflammatory diseases

Petrone, L., Diamanti, A. P., Sebastiani, G. D., Aiello, A., Laganà, B., Cuzzi, G., Vanini, V., Gualano, G., Grifoni, A., Ferraioli, M., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.04.027 · Cited by 32

A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2

Yuan, Y., Zhang, X., Chen, R., Li, Y., Wu, B., Li, R., Zou, F., Ma, X., Wang, X., Chen, Q., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110256 · Cited by 31

Rationally designed immunogens enable immune focusing following SARS-CoV-2 spike imprinting

Hauser, B. M., Sangesland, M., Denis, K. S., Lam, E. C., Case, J. B., Windsor, I. W., Feldman, J. E., Caradonna, T. M., Kannegieter, T., Diamond, M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110561 · Cited by 38

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Planas, D., Bruel, T., Grzelak, L., Guivel-Benhassine, F., Staropoli, I., Porrot, F., Planchais, C., Buchrieser, J., Rajah, M. M., Bishop, E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01318-5 · Cited by 697

Neutralization of B.1.617.2 variant through antibodies elicited by ChAdOx1‐S, BBIBP‐CorV, and Gam‐COVID‐Vac in an Argentinean cohort

Blanco, S., Aguilar, J. J., Spinsanti, L., Díaz, A., Beranek, M., Rivarola, M. E., Fernández, E. A., Mangeaud, A. P., Konigheim, B. S., & Gallego, S. V. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28286

Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variantPreprint

Edara, V. V., Lai, L., Sahoo, M. K., Floyd, K. A., Sibai, M., Solis, D., Flowers, M. W., Hussaini, L., Ciric, C. R., Bechnak, S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.09.443299 · Cited by 100

Neutralizing Antibodies Response against SARS-CoV-2 Variants of Concern Elicited by Prior Infection or mRNA BNT162b2 Vaccination

Bonura, F., Genovese, D., Amodio, E., Calamusa, G., Sanfilippo, G. L., Cacioppo, F., Giammanco, A., Grazia, S. D., & Ferraro, D. (2022) · Vaccines · doi:10.3390/vaccines10060874 · Cited by 8

In vitro neutralizing activity of BNT162b2 mRNA‐induced antibodies against full B.1.351 SARS‐CoV‐2 variant

Serrano‐Conde, E., Leyva, A., Fuentes, A. P., de Salazar, A., Chueca, N., Pérez‐Castro, S., Regueiro, B. J., Rojas, A., Mendoza, J., Rojas, J., et al. (2021) · Transboundary and Emerging Diseases · doi:10.1111/tbed.14417 · Cited by 3